Allarity Therapeutics (NASDAQ:ALLR) Stock Price Crosses Above 50-Day Moving Average – What’s Next?

Allarity Therapeutics, Inc. (NASDAQ:ALLR) shares passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $1.08 and traded as high as $1.13. Allarity Therapeutics shares last traded at $1.13, with a volume of 320,463 shares changing hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.25.

Allarity Therapeutics Stock Performance

The stock has a market cap of $17.98 million, a PE ratio of -1.45 and a beta of 0.57. The stock’s 50-day moving average is $1.08 and its two-hundred day moving average is $1.22.

Allarity Therapeutics (NASDAQ:ALLR) last posted its earnings results on Friday, August 14th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.04. Analysts forecast that Allarity Therapeutics, Inc. will post -0.80 EPS for the current year.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates.

Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology.